Australija - anglų - Department of Health (Therapeutic Goods Administration)

arrotex pharmaceuticals pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: magnesium stearate; colloidal anhydrous silica; povidone - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; magnesium stearate; colloidal anhydrous silica - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Australija - anglų - Department of Health (Therapeutic Goods Administration)

micro labs pty ltd - methenamine hippurate, quantity: 1000 mg - tablet, uncoated - excipient ingredients: povidone; colloidal anhydrous silica; magnesium stearate - prophylaxis or suppression of bacteriuria associated with chronic or recurrent infection of the urinary tract.

Didžioji Britanija - anglų - MHRA (Medicines & Healthcare Products Regulatory Agency)

viatris uk healthcare ltd - methenamine hippurate - oral tablet - 1gram

Australija - anglų - Department of Health (Therapeutic Goods Administration)

abbott australasia pty ltd - ferrous sulfate - dried,sodium ascorbate -

Kanada - anglų - Health Canada

axxess pharma inc. - methenamine; sodium bicarbonate; tartaric acid - powder (effervescent) - 0.5g; 4.6g; 3.8g - methenamine 0.5g; sodium bicarbonate 4.6g; tartaric acid 3.8g - urinary anti-infectives

Kanada - anglų - Health Canada

produits francais labs inc. - methenamine mandelate; methylene blue - tablet - 250mg; 10mg - methenamine mandelate 250mg; methylene blue 10mg - urinary anti-infectives

Kanada - anglų - Health Canada

graceway pharmaceuticals - methenamine hippurate - tablet - 1g - methenamine hippurate 1g - urinary anti-infectives

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

beach products, inc. - potassium phosphate, monobasic (unii: 4j9fj0hl51) (phosphate ion - unii:nk08v8k8hr, potassium cation - unii:295o53k152), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (phosphate ion - unii:nk08v8k8hr, sodium cation - unii:lyr4m0nh37) - potassium phosphate, monobasic 305 mg - this product is contraindicated in patients with infected phosphate stones, in patients with severely impaired renal function (less than 30% of normal) and in the presence of hyperphosphatemia.

Jungtinės Valstijos - anglų - NLM (National Library of Medicine)

apace packaging, llc - methenamine (unii: j50oix95qv) (methenamine - unii:j50oix95qv), sodium phosphate, monobasic, anhydrous (unii: kh7i04hpuu) (sodium cation - unii:lyr4m0nh37), phenyl salicylate (unii: 28a37t47qo) (phenyl salicylate - unii:28a37t47qo), methylene blue (unii: t42p99266k) (methylene blue cation - unii:zmz79891zh), hyoscyamine sulfate (unii: f2r8v82b84) (hyoscyamine - unii:px44xo846x) - uroav-b capsules are indicated for the treatment of symptoms of irritative voiding. indicated for the relief of local symptoms, such as inflammation, hypermotility, and pain, which accompany lower urinary tract infections. indicated for the relief of urinary tract symptoms caused by diagnostic procedures. uroav-b capsules are contraindicated in patients with a hypersensitivity to any of the ingredients. risk-benefit should be considered when the following medical problems exist: cardiac disease (especially cardiac arrhythmias, congestive heart failure, coronary heart disease, and mitral stenosis); gastrointestinal tract obstructive disease; glaucoma; myasthenia gravis; acute urinary retention may be precipitated in obstructive uropathy (such as bladder neck obstruction due to prostatic hypertrophy).